A market where fixed costs are so high relative to variable costs that average cost declines over the entire relevant demand curve, making one firm cheapest for society.
2
New cards
Why Competition Fails in Natural Monopoly (Natural Monopoly – Ramey)
If price is forced to P = MC, firms cannot cover fixed costs and incur losses equal to fixed cost; thus competitive entry is unsustainable.
3
New cards
Monopolist Output Rule (Natural Monopoly – Ramey)
A natural monopolist chooses Q where MR = MC, then charges the highest price consumers will pay for that quantity, creating profits and deadweight loss.
4
New cards
Deadweight Loss in Natural Monopoly (Natural Monopoly – Ramey)
The lost gains from trade between QM and QC since consumers value those units above MC but the monopolist restricts output.
5
New cards
Average Cost Pricing Regulation (Natural Monopoly – Ramey)
Government sets P = AC at Q_AC so the monopolist breaks even (profit = 0) while reducing, but not eliminating, deadweight loss.
6
New cards
Why Average Cost Pricing Still Has DWL (Natural Monopoly – Ramey)
Because P > MC, output remains below the efficient Q*, so some mutually beneficial trades are still lost.
7
New cards
When Natural Monopoly Disappears (Natural Monopoly – Ramey)
If demand expands or technology changes so AC no longer falls, competition can become sustainable.
8
New cards
Daraprim Price Hike Mechanism (“Taking on the Drug Profiteers” – Surowiecki)
Turing exploited regulatory barriers, closed distribution, and lack of FDA-approved competitors to gain monopoly power over an old generic drug.
9
New cards
Rent Seeking in Drug Markets (“Taking on the Drug Profiteers”)
Increasing profits not through innovation but by exploiting loopholes and regulatory rules that block competition.
10
New cards
Why Competitors Didn’t Enter Daraprim Market (“Taking on the Drug Profiteers”)
Small market size, high FDA approval costs, and inability to obtain drug samples prevented generic entry.
11
New cards
Patents vs Daraprim Case (“Taking on the Drug Profiteers”)
Patents reward innovation with temporary monopoly; Daraprim had no innovation justification, so monopoly pricing was pure rent-seeking.
12
New cards
Policy Solutions to Drug Price Abuse (“Taking on the Drug Profiteers”)
Regulatory reciprocity, mandatory sample access, and stronger FTC scrutiny of generic mergers to promote competition.
13
New cards
System vs Individual Problem (Shkreli Lesson) (“Taking on the Drug Profiteers”)
The issue is not one bad actor but a system enabling monopoly pricing through regulatory barriers and weak competition.
14
New cards
Perfect Competition vs Monopoly (Competition Is for Losers – Thiel)
Competitive firms are undifferentiated and earn zero long-run profits; monopolies succeed by solving unique problems others cannot.
15
New cards
Thiel’s View of Competition (Competition Is for Losers – Thiel)
Competition destroys profits; successful businesses seek to become monopolies to capture lasting value.
16
New cards
Creative Monopoly (Competition Is for Losers – Thiel)
A firm so good that no substitute exists; creates new value and drives innovation instead of extracting rents.
17
New cards
Why Monopolists Hide Market Power (Competition Is for Losers – Thiel)
They frame their market broadly (“we’re just an ad company”) to avoid regulation and antitrust scrutiny.
18
New cards
Why Entrepreneurs Underestimate Competition (Competition Is for Losers – Thiel)
Startups define markets too narrowly (“only British food in Palo Alto”), ignoring real substitutes and causing failure.
19
New cards
Dynamic vs Static Monopoly (Competition Is for Losers – Thiel)